3-[[4-(Benzylamino)quinazolin-2-yl] Amino] Benzenesulfonamide, a Quinazoline-Based PDE5 Inhibitor, Induces Vasorelaxation in Rat Mesenteric Arteries via Multiple Mechanisms.

Authors

Usana Chatturong, Krongkarn Chootip, M Paul Gleeson, Guntur Guntur, Yasuteru Shigeta, Kowit Hengphasatporn, Perle Totoson, Céline Demougeot

Published in

Basic & clinical pharmacology & toxicology. Volume 139. Issue 5.

Abstract

We synthesised a series of N²,N⁴-diaminoquinazoline derivatives, among which 3-[[4-(benzylamino)quinazolin-2-yl]amino]benzenesulfonamide (compound 5) exhibited potent phosphodiesterase type 5 (PDE5) inhibitory activity. Increasing evidence suggests that PDE5 inhibition is a promising therapeutic strategy for peripheral vascular disease. This study aimed to investigate vasorelaxant effects of 5 and its underlying mechanisms in rat mesenteric arteries. Compound 5 was synthesised and purified, and evaluated its vascular activity using organ bath assay. Molecular docking was performed to identify its potential molecular targets. Compound 5 (0.0001-30 μM) induced relaxation of phenylephrine (PE)-precontracted mesenteric arteries (EC₅₀ = 0.76 ± 0.29 μM; E_max = 95.6% ± 1.1%). This effect was attenuated by endothelium removal (EC₅₀ = 5.24 ± 0.98 μM) and by L-NAME (eNOS inhibitor). Compound 5 enhanced sodium nitroprusside-induced relaxation, supporting modulation of the NO-sGC-cGMP axis via PDE5 inhibition. Iberiotoxin (BK_Ca blocker) reduced relaxation, whereas 4-aminopyridine (K_V blocker) and glibenclamide (K_ATP blocker) had no effect. Compound 5 inhibited vasoconstriction mediated by extracellular Ca²⁺ influx via receptor-operated Ca²⁺ channels (ROCCs) and α₁-adrenergic receptor activation. Molecular docking provided qualitative support for PDE5A, BK_Ca channels and α₁-adrenergic receptor as potential targets. In conclusion, 5 induces potent vasorelaxation in resistance arteries through eNOS/NO/cGMP signalling, BK_Ca channel activation and inhibition of ROCCs and α₁-adrenergic receptors, supporting its potential as a therapeutic candidate for peripheral vascular disorders.

PMID:
42920407
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.